Literature DB >> 17166987

Increased leukotriene E4 in the exhaled breath condensate of children with mild asthma.

Atsushi Shibata1, Toshio Katsunuma, Morimitsu Tomikawa, Aiko Tan, Keisuke Yuki, Kenichi Akashi, Yoshikatsu Eto.   

Abstract

BACKGROUND: Chronic airway inflammation is a feature of asthma. Increased levels of cysteinyl leukotrienes (cys-LTs; leukotriene [LT]C(4), LTD(4), LTE(4)) have been shown in the exhaled breath condensate (EBC) of children with moderate-to-severe asthma. The aim of this study was to examine the relationship between EBC cys-LTs (LTE(4)) levels and bronchial hyperreactivity in children with mild asthma in order to evaluate the clinical utility of measuring EBC cys-LTs levels.
METHODS: We measured LTE(4) levels in the EBC of children aged 8 to 18 years, including healthy nonasthmatic children (n = 6) and children with mild asthma (n = 37). Patients with mild asthma were classified into the following three groups: group 1, participants who had been asymptomatic (no wheezing/symptoms of asthma) for > 6 months prior to examination (n = 12); group 2, participants who were asymptomatic but had had wheezing/symptoms of asthma within 6 months before examination (n = 18); and group 3, patients with current wheeze and/or mild symptoms of asthma exacerbation at the time of examination.
RESULTS: Exhaled LTE(4) levels were increased in all children with mild asthma compared with nonasthmatic control subjects (5.69 +/- 9.62 pg/20 min vs 0.74 +/- 0.79 pg/20 min, p < 0.05) [mean +/- SD]. In particular, the EBC LTE(4) levels in group 2 (4.99 +/- 6.70 pg/20 min) and group 3 (14.66 +/- 17.11 pg/20 min) were increased compared with control subjects and group 1 (1.50 +/- 1.69 pg/20 min). The EBC LTE(4) levels negatively correlated with the provocative concentration of methacholine causing a 15% fall in FEV(1) (r = - 0.454, p = 0.012).
CONCLUSION: EBC cys-LTs may be useful as a noninvasive marker assessing airway inflammation and hyperreactivity in children with asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166987     DOI: 10.1378/chest.130.6.1718

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Mass Spectrometry Analysis of the Exhaled Breath Condensate and Proposal of Dermcidin and S100A9 as Possible Markers for Lung Cancer Prognosis.

Authors:  Laura Núñez-Naveira; Luis Antonio Mariñas-Pardo; Carmen Montero-Martínez
Journal:  Lung       Date:  2019-05-21       Impact factor: 2.584

2.  Biomarkers in exhaled breath condensate: a review of collection, processing and analysis.

Authors:  N M Grob; M Aytekin; R A Dweik
Journal:  J Breath Res       Date:  2008-09-08       Impact factor: 3.262

Review 3.  Exhaled Breath Condensate: Technical and Diagnostic Aspects.

Authors:  Efstathia M Konstantinidi; Andreas S Lappas; Anna S Tzortzi; Panagiotis K Behrakis
Journal:  ScientificWorldJournal       Date:  2015-05-27

Review 4.  Role of Leukotrienes and Leukotriene Modifiers in Asthma.

Authors:  Paolo Montuschi
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-02

5.  Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients.

Authors:  Rembert Koczulla; Silvano Dragonieri; Robert Schot; Robert Bals; Stefanie A Gauw; Claus Vogelmeier; Klaus F Rabe; Peter J Sterk; Pieter S Hiemstra
Journal:  Respir Res       Date:  2009-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.